This study concluded that breast cancer survivors who are on aromatase inhibitor therapy often experience GSM symptoms and sexual dysfunction, which negatively affects their quality of life. GSM assessment should be integrated into the care for breast cancer survivors. Here, CYP19A1 is linked to breast cancer.